Home » Axcan Pharma Submits Complete New Drug Application for Ultrase
Axcan Pharma Submits Complete New Drug Application for Ultrase
Axcan Pharma Inc. (“Axcan” or the “Company”) announced that it has submitted the complete New Drug Application (“NDA”) for Ultrase in the treatment of Exocrine Pancreatic Insufficiency (“EPI”), with the U.S. Food and Drug Administration (“FDA”).
Marketwire
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May